Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody FcRn ...
PD-L1 expression and microsatellite instability in tumors of unknown primary site. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback